WEBINAR
How AbbVie Cuts Hit Validation Timelines by 60% with Cell-Free
Accelerating Discovery: Applications of Cell-Free Protein Expression Technology
Sign up:
Summary
In early drug discovery, the speed at which you can validate a target often defines the success of a program. Join Dr. Judith Ronau, Senior Scientist at AbbVie, as she details how her team utilizes cell-free protein expression to eliminate the bottlenecks of traditional cell-based production. Dr. Ronau will present a panel of case studies, including a comprehensive case study on CRISPR hit validation, demonstrating how shifting to the Nuclera eProtein Discovery™ system reduced a project timeline from 6 months to just 2 months—delivering decision-grade data on difficult-to-express proteins and 48+ mutants without leaving the bench.
In this webinar, you’ll learn how to:
- Slash Timelines: See the data behind AbbVie’s 60% reduction in CRISPR hit validation time compared to traditional E. coli workflows.
- Optimize Difficult Proteins: Discover how to screen custom additives in parallel to rescue activity for challenging targets like Cysteine Proteases and E3 ligases.
- Ensure Data Quality: Review side-by-side comparisons showing cell-free proteins yielding equivalent IC50 and Kd values to traditionally purified standards.
- Decentralize Production: Learn how to produce "assay-ready" proteins (<1 mg) locally, bypassing the queue for central protein facilities or CROs.
This webinar is designed for:
- Discovery & Hit-to-Lead Scientists and Executives in pharma/biotech who need to validate CRISPR hits and therapeutic targets without the 6-month wait.
- Targeted Protein Degradation (TPD) Researchers struggling to express and characterize complex E3 ligases and ubiquitination machinery.
- Protein Sciences & Platform Teams looking to decentralize small-scale (<1 mg) production to relieve pressure on internal core facilities.
- Biophysicists & Structural Biologists who need a rapid way to screen constructs and additives for "impossible" or insoluble proteins.
Speaker:
Recent publications:
- Yarawsky, A. E. et al. A paradigm shift: analytical ultracentrifugation as a multi-attribute platform method in targeted protein degradation. Eur. Biophys. J. (2025).
- Lynch, T. L. et al. Quantitative measurement of rate of targeted protein degradation. ACS Chem. Biol. 19, 1604–1615 (2024).
- Shergalis, A.G.. et al. CRISPR screen reveals BRD2/4 molecular glue-like degrader via recruitment of DCAF16. ACS Chem. Biol. 18, 331–339 (2023).
- Berk, J.M. et al. A deubiquitylase with an unusually high affinity ubiquitin-binding domain from the scrub typhus pathogen Orientia tsutsugamushi.” Nat Commun. 11, 2343 (2020).
About eProtein Discovery
Nuclera's eProtein Discovery™ system combines digital microfluidic droplet automation with cell-free protein synthesis technologies, it empowers protein scientists to identify the best conditions for expressing and purifying proteins of interest within 24 hours, all on a single consumable cartridge.
The system offers a significant advantage over traditional protein expression methods, allowing researchers to save time and resources by simplifying and automating the process. Its ability to handle multiple genes and customizable cell-free blends makes it a valuable tool for protein scientists in academia and the biopharma industry.
